Akebia Therapeutics Inc. AKBA

NAS: AKBA | ISIN: US00972D1054   26/05/2023
1,130 USD (-6,61%)
(-6,61%)   26/05/2023

25 mei 2023 · Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia · Persbericht

22 mei 2023 · Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

22 mei 2023 · Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis · Persbericht

8 mei 2023 · Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

1 mei 2023 · Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights · Persbericht

25 april 2023 · Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis · Persbericht

14 april 2023 · Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split · Persbericht

11 april 2023 · Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders · Persbericht

7 april 2023 · Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023 · Persbericht

4 april 2023 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 april 2023 · Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study · Persbericht

30 maart 2023 · Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat · Persbericht

24 maart 2023 · Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting · Persbericht

9 maart 2023 · Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights · Persbericht

2 maart 2023 · Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights · Persbericht

23 februari 2023 · Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis · Persbericht

21 februari 2023 · Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease · Persbericht

1 februari 2023 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 januari 2023 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

22 december 2022 · Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA · Persbericht

Mijn selecties